Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

21Shares Injective ETF

CIK 2061622Updated Oct 6, 2026

No exchange listing on record for this SEC filer. Coverage is drawn from its filings.

Filing activity

SEC EDGAR
Latest filing

S-1/A · Sep 18, 2026

1 filing on record · S-1/A.

About the company

21Shares Injective ETF (the “Trust”) is an exchange-traded fund that issues common shares of beneficial interest (the “Shares”) that are expected to trade on the Nasdaq Stock Market LLC (the “Exchange”). The Trust’s investment objective is to seek to track the performance of INJ, as measured by the performance of the FTSE Injective Index (the “Pricing Benchmark”), as adjusted for the Trust’s expenses and other liabilities, and to reflect rewards from staking a portion of the Trust’s INJ, to the extent the Sponsor in its sole discretion determines that the Trust may do so without undue legal or regulatory risk, such as, without limitation, the risk of jeopardizing the Trust’s ability to qualify as a grantor trust for tax purposes. The Pricing Benchmark is calculated by FTSE International Limited (the “Benchmark Provider” or “FTSE”). The Pricing Benchmark is designed to track the performance of INJ in U.S. dollars. The Shares of the Trust are valued daily based on the Pricing Benchmark.

S-1/A · 2026-09-18 · 0001213900-26-101489

Company description from the cited filing.

Recent filings

  1. S-1/A filing

    S-1/A · 2026-09-18 · 0001213900-26-101489

Offerings

Registration 333-290955

S-1/A · 2026-09-18 · 0001213900-26-101489

Terms from the governing filing for this registration; not a claim that the offering is open today.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.